Longevity science represents one of the greatest financial opportunities of all time, but also presents novel financial, development, regulatory, and clinical challenges to biotechnology/pharmaceutical entrepreneurs.
In this workshop you will learn more the fundamentals of launching and growing a successful biotechnology/pharmaceutical business with an emphasis on nuances specific to the emerging longevity science industry.
Key topics to be discussed include:
Join us for this interactive discussion and learning session that will bring practical insights into the development and bringing to life of a successful pipeline in the anti-aging space.
Kelsey Moody, CEO, Antoxerene/Ichor Therapeutics
Mr. Moody is a process-oriented biotechnology executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Mr. Moody has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated research organization that focuses on pre-clinical drug discovery for pathways of aging. R&D initiatives that constitute Ichor’s portfolio companies span enzyme therapy (Lysoclear, Inc.), small molecule drug discovery (Antoxerene, Inc.), antibody mimetics (Auctus Biologics, Inc.), protein chemistry tools (RecombiPure, Inc.), and a pre-seed strategic investment fund (Grapeseed.Bio). Mr. Moody has received graduate-level training in medicine, business, and laboratory research.